Kailera Therapeutics: The record-breaking obesity IPO big pharma cannot ignore
MSN·- Kailera Therapeutics trades 29 % below its IPO high while holding $1.17 billion in cash and a $42 analyst consensus price target. - Merck and Novo Nordisk emerge as natural buyers for Kailera's GLP - 1 pipeline due to impending revenue challenges and market defense needs. - Any potential acquirer will secure global rights across the U.S., Europe, and Japan while inheriting significant financial obligations.